KURA biotech catalysts & pipeline

KURA ONCOLOGY INC · Data as of 2026-09-08

Upcoming catalysts

KO-7246 — IND submission

2026

We have nominated our first next-generation menin inhibitor, KO-7246, which we expect to advance into investigational new drug application, or IND, -enabling studies in diabetes and cardiometabolic diseases in 2026 with external investment or through a collaboration.

Source filing

darlifarnib — Full data

2H 2026

• Present updated Phase 1a data with the first report of long-term follow-up for darlifarnib plus cabozantinib in advanced RCC (2H 2026)

Source filing

KOMZIFTI (ziftomenib) — Full data

H2 2026

We anticipate presenting updated long-term data from the KOMET-007 Phase 1b trial, including durability, survival, and MRD outcomes, in the second half of 2026.

Source filing

darlifarnib — Initial data

2H 2027

• Complete enrollment in the randomized FIT-001 Phase 1b study evaluating darlifarnib plus cabozantinib in cabozantinib-naïve ccRCC in 1H 2027 and report initial clinical data in 2H 2027

Source filing

KOMZIFTI (ziftomenib) — Topline data

in 2028

Based on our current assumptions, we anticipate topline results from the MRD-negative CR accelerated endpoint in the intensive chemotherapy setting in 2028.

Source filing

KO-7246 — Conference presentation

2026

We anticipate the presentation of preclinical data on the use of menin inhibitors in diabetes in 2026.

Source filing

menin inhibitors — Conference presentation

in 2026

We anticipate the presentation of preclinical data on the use of menin inhibitors in diabetes in 2026.

Source filing

Explore the free biotech catalyst calendar